Cambridge Healthtech Institute’s Third Annual
Immunogenicity Prediction & Mitigation
Understanding and Control from Pioneers in the Field
Part of the 11th Annual PEGS: the essential protein engineering summit
May 4-5, 2015 | World Trade Center | Boston, Massachusetts


Innovators in the field of immunogenicity are constantly furthering our understanding of factors that contribute to immunogenicity, and developing new and advanced aapproaches for predicting immunogenicity, for reducing immunogenicity, and for tolerance induction. Presentations at Immunogenicity Prediction and Mitigation will enable attendees to make informed decisions on candidate selection, dosing and formulation, with a view to producing safe and efficacious products in the clinic and beyond.

I am looking for NEW case studies and practical experience on the following: 

  • Identification of risk factors that contribute to immunogenicity such as T cell epitopes, particles and impurities, formulation, dosing, and route of administration
  • Sub-visible particles, aggregates and immunogenicity: advances in technology for characterization, studies on their impact on immunogenicity, factors that contribute to aggregation, and risk assessments and risk mitigation plans based on propensity to aggregate
  • Tools and approaches for immunogenicity risk prediction including mathematical models, epitope-based databases, animal models and novel approaches
  • Controlling immunogenicity and immunosuppressive mechanisms, especially for specific products such as interferon beta
  • New approaches to tolerance induction such as antibody engineering, identification and silencing of T cell epitopes, deimmuniation and novel approaches.

Scientists who wish to present their knowledge and expertise to their colleagues are asked to click here to submit an abstract. Remember to specify the conference that you are interested in and please provide your full contact information.

The deadline for submission is October 3, 2014. 

All proposals are subject to review by the Scientific Advisory Committee to ensure the highest quality of the conference program. Please note that due to limited speaking slots, preference is given to pharmaceutical and biotech companies, regulators and those from academia. Additionally, vendors/consultants who provide products and services to these biopharmaceutical companies are offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships. 

For more details on the conference, please contact:
Nicole Lyscom, Ph.D.
Conference Director
Cambridge Healthtech Institute
T: +44 7791 866489
E: nlyscom@healthtech.com 

For partnering and sponsorship information, please contact:
Jason Gerardi (Companies A-K)
Manager, Business Development
Cambridge Healthtech Institute
T: 781-972-5452
E: jgerardi@healthtech.com 

Carol Dinerstein (Companies L-Z)
Director, Business Development
Cambridge Healthtech Institute
T: 781.972.5471
E: dinerstein@healthtech.com